Physician profile
David Loyd Doering
NPI 1407813025
$3,939.79
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,378 · 2020: $825 · 2021: $266 · 2022: $429 · 2023: $468 · 2024: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,040.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $816.34 | 2019-2024 | Tisseel, Perclot, Floseal |
| Clovis Oncology, INC. | $785.37 | 2019-2022 | |
| Glaxosmithkline, LLC. | $511.30 | 2020-2023 | Jemperli |
| Astrazeneca Pharmaceuticals LP | $326.45 | 2019-2024 | Lynparza |
| Tesaro, INC. | $244.02 | 2019 | |
| Eisai INC. | $211.68 | 2022-2023 | |
| Hologic Sales and Service, LLC | $185.50 | 2019-2020 | |
| Stryker Corporation | $151.80 | 2020 | |
| Kite Pharma, INC. | $124.27 | 2019 | |
| Coopersurgical, INC. | $120.04 | 2019 | |
| Genmab U.S., INC. | $118.42 | 2024 | Tivdak |
| Myriad Genetic Laboratories, INC. | $91.33 | 2023 | Myrisk |
| Novocure INC. | $82.05 | 2020 | |
| Amgen INC. | $73.99 | 2022 | |
| Intuitive Surgical, INC. | $45.40 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.08 | 2024 | |
| Jazz Pharmaceuticals INC. | $17.25 | 2019 | |
| Merck Sharp & Dohme LLC | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Doering listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.